Akeso’s cancer therapy gets orphan status from US FDA
PositiveFinancial Markets
Akeso's cancer therapy has received orphan drug designation from the US FDA, which can accelerate its development and approval process.
Editor’s Note: This designation is significant as it provides incentives for companies to develop treatments for rare diseases, potentially leading to faster access for patients in need.
— Curated by the World Pulse Now AI Editorial System